~~<i id='5EDE0BC777'><strike id='5EDE0BC777'><tt id='5EDE0BC777'><pre id='5EDE0BC777'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：explore 2025-10-01 03:39:48 Page View：693

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

Featured Speakers

Irena Melnikova, Ph.D., partner, Pfizer Ventures
Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Plane’s emergency slide plummets from sky, hits Chicago home
Next article： Apple is now the first public company to be valued at $3 trillion

explore

New air purifier tech could be key to improving indoor air quality

AdobeUntiltheearly20thcentury,Americaregularlyexperiencedbrutallydestructiveurbanfires.Conflagration

Medical experts are missing from AI regulatory conversations

SenateMajorityLeaderChuckSchumerinJuneannouncedtheSAFEInnovationframeworkto“supportresponsiblesystem

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

Ebola public health emergency is over, WHO declares

AhealthworkerinprotectiveclothingspeakswithnewarrivalsintheoutpatientwaitingroomofanEbolaholdingcent